B cells may help predict risk of colitis from immunotherapy

These differences suggest B cells may play a regulatory role in gut

Researchers at The University of Texas MD Anderson Cancer Center have identified a potential biomarker for immunotherapy-induced colitis using B cell activity. The discovery could allow doctors to anticipate which patients are at higher risk of developing this serious side effect before treatment begins. The findings stem from analyzing immune responses in cancer patients receiving checkpoint inhibitors. The study focused on how B cells, a type of white blood cell involved in antibody production, behave differently in patients who later develop colitis compared to those who do not. Researchers observed distinct patterns in B cell activation and signaling pathways prior to symptom onset.

Health news

Vegan Diets May Reduce Gut Bacteria Diversity, Study FindsMusic with beats cuts stress hormone more than pink noiseEpigenetic Shifts Can Trigger Liver Cancer Without DNA DamageBlood Clots and Brain Tumors Linked by Overactive Platelets

These differences suggest B cells may play a regulatory role in gut inflammation triggered by immunotherapy, offering a window for early intervention. Can B cell profiles forecast gut toxicity before treatment starts? By examining blood samples from patients undergoing immunotherapy, scientists found that specific B cell subsets were more prevalent in individuals who avoided colitis. These protective B cells appeared to secrete molecules that dampen inflammatory responses in the colon. Conversely, patients who developed colitis showed reduced numbers of these regulatory B cells and heightened activity in pro-inflammatory B cell populations. The team validated these patterns across multiple cohorts, strengthening the link between B cell dynamics and colitis risk. What does this mean for future cancer therapy strategies? If confirmed in larger trials, B cell profiling could become a routine pre-treatment test to personalize immunotherapy approaches.

Patients identified as high-risk might receive preventive measures such as

Patients identified as high-risk might receive preventive measures such as probiotics, dietary adjustments, or early use of anti-inflammatory drugs. This proactive strategy aims to maintain the cancer-fighting benefits of immunotherapy while minimizing debilitating gastrointestinal complications. Researchers emphasize that further study is needed to refine the biomarker and test its predictive accuracy in real-world clinical settings. Frequently Asked Questions How do B cells relate to colitis in immunotherapy patients? B cells influence immune balance in the gut; certain subtypes help suppress inflammation, while others may promote it. Changes in their activity can signal impending colitis before symptoms appear. Could this discovery lead to preventive treatments for colitis? Yes, identifying at-risk patients early could allow doctors to intervene with preventive strategies, potentially reducing colitis incidence without compromising immunotherapy effectiveness. Is B cell testing currently available for cancer patients?

Not yet; the approach remains experimental and requires further validation in clinical trials before it can be used routinely in patient care.